Schrödinger Q1 revenue $36.6M, net loss $54.7M; FDA clears IND for SGR-3515

Schrodinger, Inc.

2024-Q1 EPS reported -$0.76 revenue$36,598,000

Total revenue $36.6M (down 44% YoY); software revenue $33.4M (+3.7%).
Net loss $54.7M vs net income $129.1M in Q1 2023; non-GAAP net loss $62.4M.
FDA cleared IND for SGR-3515 (Wee1/Myt1 inhibitor); Phase 1 solid tumors trial expected Q3 2024.
SGR-1505 and SGR-2921 Phase 1 data readouts expected late 2024 or 2025.
Rights to SOS1 inhibitor reverted from BMS after portfolio prioritization.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Schrodinger, Inc. reported first quarter ended March 31, 2024 results: revenue $36.6 million, net income $(54.7) million. Guidance reaffirmed.

Period: first quarter ended March 31, 2024
Revenue: $36.6 million
Net income: $(54.7) million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

expressly incorporated by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Schrödinger Reports First Quarter 2024 Financial Results First Quarter Total Revenue of $36.6 Million, Software Revenue of $33.4 Million Announces FDA Clearance of Investigational New Drug Application for SGR-3515, a Novel Wee1/Myt1 Inhibitor SGR-1505 and SGR-2921 on Track for

View on SEC.gov

379 earnings releases filed in the last 30 days. Browse all earnings releases →

Schrodinger, Inc. filing history →

Source: SEC EDGAR

accession 0001490978-24-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.